MannKind Corp (MNKD) EVP receives 70,550 shares from performance RSUs

Q: What equity award did MannKind (MNKD) EVP Sanjay R. Singh have vest in this Form 4?

Sanjay R. Singh had a performance-based restricted stock unit award granted on May 25, 2023 vest on July 15, 2026, delivering 70,550 common shares . The performance objective was achieved at 83% of target , based on stock price and total shareholder return versus a Russell 3000 pharma/biotech index.

Q: How many MannKind (MNKD) shares were withheld for taxes in Singh's Form 4?

The Form 4 reports 46,795 shares of MannKind common stock withheld to cover tax obligations. These were recorded in four transactions using code F at a reported value of $4.09 per share , described as payment of tax liability by delivering or withholding securities.

Q: How many restricted stock units were forfeited by MannKind (MNKD) EVP Singh?

Out of an original 85,000 restricted stock units granted May 25, 2023, 14,450 units were forfeited. Footnotes explain the performance objective was achieved at 83% of target , resulting in delivery of 70,550 shares and forfeiture of the remaining units under the vesting criteria.

Q: Were Singh's MannKind (MNKD) transactions reported as Rule 10b5-1 plan trades?

No. The Form 4's Rule 10b5-1 checkbox is not marked , so these transactions were not reported as being made pursuant to a Rule 10b5-1 trading plan. They are instead tied to the scheduled vesting of previously granted performance restricted stock units.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

MannKind Corp EVP Technical Operations Sanjay R. Singh reported vesting of a performance-based restricted stock unit award granted in May 2023, delivering 70,550 common shares on July 15, 2026. Footnotes state performance goals were achieved at 83% of target, with 14,450 units forfeited. To satisfy tax obligations, 46,795 shares were withheld at $4.09 per share and characterized as payments of tax liability by delivering or withholding shares under Rule 16b-3. Each restricted stock unit represented one share of common stock.

Insider Trade Summary

70,550 shares exercised/converted

Mixed 6 txns

Insider Singh Sanjay R

Role EVP Technical Operations

Type	Security	Shares	Price	Value
Exercise	Performance Restricted Stock Unit	70,550	$0.00	--
Exercise	Common Stock, $0.01 Par Value	70,550	$0.00	--
Tax Withholding	Common Stock, $0.01 Par Value	22,047	$4.09	$90K
Tax Withholding	Common Stock, $0.01 Par Value	5,372	$4.09	$22K
Tax Withholding	Common Stock, $0.01 Par Value	10,079	$4.09	$41K
Tax Withholding	Common Stock, $0.01 Par Value	9,297	$4.09	$38K

Holdings After Transaction: Performance Restricted Stock Unit — 0 shares (Direct); Common Stock, $0.01 Par Value — 525,761 shares (Direct)

Footnotes (1)

A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 70,550 shares. The acquisition of 85,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 14,450 shares were forfeited in accordance with the performance vesting criteria. Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

Key Figures

Performance RSUs Delivered: 70,550 shares Original RSU Award: 85,000 units Forfeited RSUs: 14,450 units +4 more

7 metrics

Performance RSUs Delivered 70,550 shares Shares delivered upon vesting of a performance-based restricted stock unit award on July 15, 2026

Original RSU Award 85,000 units Performance restricted stock unit award granted May 25, 2023

Forfeited RSUs 14,450 units Unvested portion forfeited under the performance vesting criteria

Tax-Withholding Shares 46,795 shares Shares withheld to cover tax obligations related to vesting

Tax-Withholding Price $4.09 per share Price reported for tax-withholding dispositions on July 15, 2026

Performance Achievement 83% of target Level at which the performance objective for the RSU award was achieved

TSR Percentile 41.5th percentile MannKind TSR vs Russell 3000 Pharmaceutical & Biotechnology Index from May 23, 2023 to June 30, 2026

Key Terms

Performance Restricted Stock Unit, total shareholder return (TSR), Russell 3000 Pharmaceutical & Biotechnology Index, Rule 16b-3

4 terms

Performance Restricted Stock Unit financial

"Security title shown as Performance Restricted Stock Unit in the derivative transaction row"

total shareholder return (TSR) financial

"MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026"

Total shareholder return (TSR) measures how much an investment in a company's stock has grown over a specific period by combining the change in the share price and all dividends paid, expressed as a percentage. Think of it like tracking the total balance of a savings jar that increases both from added cash (dividends) and a rising sticker price on the jar (share price); investors use TSR to compare how well different stocks or managers deliver real, money-in-hand returns.

Russell 3000 Pharmaceutical & Biotechnology Index financial

"TSR was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index"

Rule 16b-3 financial

"security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units"

Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/17/2026 - 09:44 PM Accepted by SEC EDGAR 07/17/2026 - 09:44 PM

FAQ

What equity award did MannKind (MNKD) EVP Sanjay R. Singh have vest in this Form 4?

Sanjay R. Singh had a performance-based restricted stock unit award granted on May 25, 2023 vest on July 15, 2026, delivering 70,550 common shares. The performance objective was achieved at 83% of target, based on stock price and total shareholder return versus a Russell 3000 pharma/biotech index.

How many MannKind (MNKD) shares were withheld for taxes in Singh's Form 4?

The Form 4 reports 46,795 shares of MannKind common stock withheld to cover tax obligations. These were recorded in four transactions using code F at a reported value of $4.09 per share, described as payment of tax liability by delivering or withholding securities.

How many restricted stock units were forfeited by MannKind (MNKD) EVP Singh?

Out of an original 85,000 restricted stock units granted May 25, 2023, 14,450 units were forfeited. Footnotes explain the performance objective was achieved at 83% of target, resulting in delivery of 70,550 shares and forfeiture of the remaining units under the vesting criteria.

What performance conditions applied to MannKind (MNKD) EVP Singh's RSU award?

The award required that MannKind's stock closing price on June 30, 2026 not be below May 25, 2023 and that total shareholder return from May 23, 2023 to June 30, 2026 reach the 41.5th percentile of the Russell 3000 Pharmaceutical & Biotechnology Index, leading to 83% payout.

Were Singh's MannKind (MNKD) transactions reported as Rule 10b5-1 plan trades?

No. The Form 4's Rule 10b5-1 checkbox is not marked, so these transactions were not reported as being made pursuant to a Rule 10b5-1 trading plan. They are instead tied to the scheduled vesting of previously granted performance restricted stock units.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Singh Sanjay R

(Last)

(First)

(Middle)

1 CASPER STREET

(Street)

DANBURY

CONNECTICUT

06810

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MANNKIND CORP [ MNKD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP Technical Operations

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, $0.01 Par Value	07/15/2026		M⁽¹⁾		70,550	A	$0	525,761	D
Common Stock, $0.01 Par Value	07/15/2026		F⁽²⁾		22,047	D	$4.09	503,714	D
Common Stock, $0.01 Par Value	07/15/2026		F⁽²⁾		5,372	D	$4.09	498,342	D
Common Stock, $0.01 Par Value	07/15/2026		F⁽²⁾		10,079	D	$4.09	488,263	D
Common Stock, $0.01 Par Value	07/15/2026		F⁽²⁾		9,297	D	$4.09	478,966	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Performance Restricted Stock Unit	⁽³⁾	07/15/2026		M⁽¹⁾			70,550	⁽¹⁾	⁽¹⁾	Common Stock, $0.01 Par Value	70,550	$0	0⁽¹⁾	D

Explanation of Responses:

1. A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 70,550 shares. The acquisition of 85,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 14,450 shares were forfeited in accordance with the performance vesting criteria.

2. Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

3. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

	/s/ Sanjay R Singh	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR